Cargando…
Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer
Ovarian cancer is one of the most common reproductive system tumors. The incidence of ovarian cancer in China is on the rise. Poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) is a DNA repair enzyme associated with DNA damage repair. PARPi takes PARP as a target to kill tumor cells, especially fo...
Autores principales: | Dong, Ruihong, Ding, Ting, Li, Zhengyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326311/ https://www.ncbi.nlm.nih.gov/pubmed/37426808 http://dx.doi.org/10.3389/fphar.2023.1164395 |
Ejemplares similares
-
Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations
por: Xu, Qin, et al.
Publicado: (2021) -
Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
por: Jannetti, Stephen A., et al.
Publicado: (2020) -
Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305
por: Zheng, Jingcao, et al.
Publicado: (2023) -
Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer
por: Markman, Maurie
Publicado: (2018) -
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
por: Papa, Anselmo, et al.
Publicado: (2016)